ResMed (RMD) Form 4 shows 1,073 RSUs granted to director

Q: What did ResMed Inc. (RMD) disclose in this Form 4 filing?

ResMed Inc. disclosed that director Harjit Gill received an award of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025 .

Q: How many ResMed (RMD) RSUs were granted to director Harjit Gill?

Director Harjit Gill was granted 1,073 restricted stock units (RSUs) of ResMed common stock.

Q: At what price were the ResMed (RMD) RSUs granted to Harjit Gill?

The 1,073 RSUs granted to Harjit Gill were reported at a grant price of $0 per unit, typical for equity awards rather than market purchases.

Q: When do Harjit Gill’s ResMed (RMD) RSUs vest?

The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date.

Q: How many ResMed (RMD) shares does Harjit Gill beneficially own after this transaction?

Following the RSU award, Harjit Gill beneficially owns 10,940 shares of ResMed common stock.

Q: What is the relationship of Harjit Gill to ResMed Inc. (RMD)?

Harjit Gill is a director of ResMed Inc., as indicated in the filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported that director Harjit Gill received an equity award in the form of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025. The RSUs were granted at a price of $0 per unit, reflecting a typical director equity grant rather than an open‑market purchase.

After this award, Gill beneficially owns 10,940 shares of ResMed common stock. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to continued board service over roughly a one‑year cycle.

Insider Trade Summary

Net Buyer: 1,073 shares

Net Buy 1 txn

Insider Gill Harjit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock	1,073	$0.00	$0.00

Holdings After Transaction: ResMed Common Stock — 10,940 shares (Direct)

Footnotes (1)

F1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/24/2025 - 11:12 AM

FAQ

What did ResMed Inc. (RMD) disclose in this Form 4 filing?

ResMed Inc. disclosed that director Harjit Gill received an award of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025.

How many ResMed (RMD) RSUs were granted to director Harjit Gill?

Director Harjit Gill was granted 1,073 restricted stock units (RSUs) of ResMed common stock.

At what price were the ResMed (RMD) RSUs granted to Harjit Gill?

The 1,073 RSUs granted to Harjit Gill were reported at a grant price of $0 per unit, typical for equity awards rather than market purchases.

When do Harjit Gill’s ResMed (RMD) RSUs vest?

The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date.

How many ResMed (RMD) shares does Harjit Gill beneficially own after this transaction?

Following the RSU award, Harjit Gill beneficially owns 10,940 shares of ResMed common stock.

What is the relationship of Harjit Gill to ResMed Inc. (RMD)?

Harjit Gill is a director of ResMed Inc., as indicated in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gill Harjit

(Last)

(First)

(Middle)

9001 SPECTRUM CENTER BLVD.

C/O RESMED INC

(Street)

SAN DIEGO

92123

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	11/20/2025		A⁽¹⁾		1,073	A	$0	10,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

	Harjit Gill, director	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR